69 related articles for article (PubMed ID: 20493440)
1. [Renal cell carcinoma: antiangiogenic therapies and management of the complications. A case report].
Fendler JP; Malavaud B; Gimel P; Duclos B; Chevreau C; Pignot G
Prog Urol; 2010 Mar; 20 Suppl 1():S27-32. PubMed ID: 20493440
[TBL] [Abstract][Full Text] [Related]
2. [Renal cell carcinoma: which criteria to define antiangiogenic treatment failure? A case report].
Lang H; Lassau N; Thibault F; Delva R; Pignot G
Prog Urol; 2010 Mar; 20 Suppl 1():S23-6. PubMed ID: 20493439
[TBL] [Abstract][Full Text] [Related]
3. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
Appleby L; Morrissey S; Bellmunt J; Rosenberg J
Hematol Oncol Clin North Am; 2011 Aug; 25(4):893-915. PubMed ID: 21763973
[TBL] [Abstract][Full Text] [Related]
4. Novel antiangiogenic therapies for renal cell cancer.
Gordon MS
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6377S-81S. PubMed ID: 15448034
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
6. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A
Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377
[TBL] [Abstract][Full Text] [Related]
7. Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy?
Soulières D
Curr Opin Support Palliat Care; 2009 Sep; 3(3):153-6. PubMed ID: 19512932
[TBL] [Abstract][Full Text] [Related]
8. [Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management].
Audenet F; Rouprêt M; Méjean A
Prog Urol; 2009 Oct; 19(9):596-605. PubMed ID: 19800548
[TBL] [Abstract][Full Text] [Related]
9. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
Ainsworth NL; Lee JS; Eisen T
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
[TBL] [Abstract][Full Text] [Related]
10. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
Ebbinghaus SW; Gordon MS
Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
[TBL] [Abstract][Full Text] [Related]
11. New therapies after failure of angiogenesis inhibitors.
Escudier B
Clin Adv Hematol Oncol; 2009 Aug; 7(8):512-4. PubMed ID: 19927977
[No Abstract] [Full Text] [Related]
12. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
Ebbinghaus S; Hussain M; Tannir N; Gordon M; Desai AA; Knight RA; Humerickhouse RA; Qian J; Gordon GB; Figlin R
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6689-95. PubMed ID: 18006769
[TBL] [Abstract][Full Text] [Related]
13. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
[No Abstract] [Full Text] [Related]
14. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
Choueiri TK; Duh MS; Clement J; Brick AJ; Rogers MJ; Kwabi C; Shah K; Percy AG; Antràs L; Jayawant SS; Chen K; Wang ST; Luka A; Neary MP; McDermott D; Oh WK
BJU Int; 2010 May; 105(9):1247-54. PubMed ID: 19863525
[TBL] [Abstract][Full Text] [Related]
16. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
17. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
Choueiri TK; Bukowski RM; Rini BI
Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
[TBL] [Abstract][Full Text] [Related]
18. Current immunotherapeutic strategies in renal cell carcinoma.
Amato RJ
Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentially.
Figlin RA
Clin Adv Hematol Oncol; 2009 Oct; 7(10):662-5. PubMed ID: 20040906
[No Abstract] [Full Text] [Related]
20. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.
Soltau J; Zirrgiebel U; Esser N; Schächtele C; Totzke F; Unger C; Merfort I; Drevs J
Anticancer Res; 2008; 28(2A):933-41. PubMed ID: 18507039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]